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Abstract
Introduction: Rheumatoid arthritis (RA) is characterized by bone and cartilage invasion by fibroblast-like
synoviocytes (FLSs). Adrenomedullin, a peptide with anabolic and antiapoptotic properties, is secreted by
rheumatoid FLSs. Adrenomedullin also increases the expression of adhesion molecules in endothelial cells and
keratinocytes. Here, we investigated whether adrenomedullin mediated FLS adhesion to extracellular matrix (ECM)
proteins.
Methods: FLSs were isolated from synovial tissues from RA and osteoarthritis (OA) patients. Plates were coated
overnight with the ECM proteins vitronectin, fibronectin, and type I collagen (Coll.I). Adrenomedullin was used as a
soluble FLS ligand before plating. We tested interactions with the adrenomedullin receptor antagonist (22-52)
adrenomedullin and with the protein kinase A (PKA) inhibitor H-89, and inhibition of co-receptor RAMP-2 by siRNA.
Cell adhesion was measured by using color densitometry. Activation of a2 and b1 integrins was evaluated by
fluorescent microscopy; integrin inhibition, by RGD peptides; and the talin-integrin interaction, by
immunoprecipitation (IP).
Results: Adrenomedullin specifically increased RA-FLS adhesion to vitronectin, fibronectin, and Coll.I; no such effect
was found for OA-FLS adhesion. Basal or adrenomedullin-stimulated RA-FLS adhesion was inhibited by (22-52)
adrenomedullin, H-89, and RAMP-2 siRNA. Adrenomedullin-stimulated adhesion was inhibited by RGD peptides,
and associated with a2 and b1 integrin activation. This activation was shown with IP to be related to an integrin-
talin interaction and was significantly decreased by (22-52)adrenomedullin.
Conclusions: Adrenomedullin-stimulated RA-FLS adhesion was specific for ECM proteins and mediated by a2 and
b1 integrins. This effect of adrenomedullin was dependent on adrenomedullin receptors. These results support a
new role for adrenomedullin in rheumatoid synovial fibroblast pathobiology.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory joint
disease in which fibroblast-like synoviocytes (FLSs)
invade the extracellular matrix (ECM) of cartilage and
bone, causing destruction of both tissues. FLSs in
patients with RA (RA-FLSs) differ from normal FLSs
regarding both morphologic and biologic characteristics
[1]. More specifically, RA-FLSs can adhere to ECM pro-
teins [1,2] by a number of adhesion molecules.
Among the adhesion molecules expressed by FLSs,
integrins interact with several ECM proteins, including
collagen, fibronectin, and vitronectin. Integrins are het-
erodimeric proteins composed of two subunits, a and b.
When integrins bind to their ligands, they undergo
activation with conformational changes regulated by
inside-out signals [3]. Changes in extracellular domain
conformation are initiated by binding of talin to an integ-
rin b cytoplasmic domain [4,5]. Binding of talin to integ-
rin disrupts the salt bridge between the two chains,
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overexpress the integrins a1b1, a2b1, a3b1,a n davb3 [7].
The activation and adhesion properties of RA-FLSs may
be intrinsic to these cells or related to factors such as
cytokines and other molecules produced by RA-FLSs.
Adrenomedullin may be one such factor.
Adrenomedullin is a 52-amino acid peptide first identi-
fied in 1993 in human pheochromocytoma. This peptide
contains two structures important for its activity: a loop
of six amino acids formed by a disulfide bond between
residues 16 and 21 and an amide bond on the C-terminal
tyrosine residue [8]. The (22-52)adrenomedullin trun-
cated peptide does not have the six-amino acid ring and
can act as an antagonist of the adrenomedullin receptor,
depending on the cell type and species. In FLSs, adreno-
medullin binds to a heterodimeric plasma membrane
receptor composed of the seven-transmembrane domain
protein calcitonin receptor-like receptor (CLR) coupled
to one of two receptor activity-modifying proteins
(RAMP-2 or -3) [9]. CLR signal transduction is mediated
through G protein-coupled adenylate cyclase (AC) and
protein kinase A (PKA) pathways [10].
Several reports support a role for adrenomedullin in
the pathogenesis of RA. Plasma adrenomedullin levels
are higher in RA than in other inflammatory diseases
(lupus and scleroderma), osteoarthritis (OA), and in
normal individuals [11]. Furthermore, adrenomedullin
levels in plasma and synovial fluid are higher in RA
than in OA [12].
More recently, our group reported overexpression in
RA-FLSs of adrenomedullin and its CLR/RAMP-2,3 recep-
tor mRNA and protein, compared with FLSs from OA
patients (OA-FLS) [10]. Adrenomedullin was secreted by
RA-FLSs and may act as a soluble factor. Indeed, the adre-
nomedullin receptor was functional, because adrenome-
dullin stimulation led to intracellular cAMP production
and to decreased FLS apoptosis triggered by various condi-
tions through PKA. Moreover, (22-52)adrenomedullin
competitively and dose-dependently blocked the antiapop-
totic effect of adrenomedullin on RA-FLSs.
Interestingly, adrenomedullin has several other effects,
depending on the cell type: it increases cell proliferation
[13]; inhibits smooth muscle cell migration [14]; and sti-
mulates human umbilical vein endothelial cell (HUVEC)
proliferation and migration [15], as well as angiogenesis
in vitro [15] and in vivo [16]. Adrenomedullin also
induces the expression of adhesion molecules (intercel-
lular adhesion molecule, or ICAM; and endothelial
selectin, or E-selectin) at the surface of HUVECs [17]
and human oral keratinocytes [18].
The objective of this study was to determine whether
adrenomedullin was involved in the adhesion of RA-
FLSs to ECM proteins of bone and cartilage.
Materials and methods
Synovial specimens
Synovial tissues were obtained under aseptic conditions
from 11 RA and three OA patients undergoing total knee-
or hip-replacement surgery or wrist synovectomy. All RA
patients fulfilled the 1987 American College of Rheuma-
tology criteria for RA [19], and all OA patients had joint
pain with radiologic evidence of degenerative changes at
surgery. Disease activity and medications at surgery were
not recorded. All human sample-collection procedures
complied with the Helsinki Declaration. According to
French Law on human research (Law 2007-1110, article
1211-2), synovial sample collection (surgical waste) was
authorized unless opposition from patients occurred; all
patients were informed.
Primary synovial fibroblast cultures
Synovial tissues were minced in HAM F-12 culture med-
ium and then incubated overnight at 37°C with 1 mg/ml
of type I collagenase (Sigma-Aldrich). After cell dissocia-
tion, the samples were filtered through a cell strainer. Cell
suspensions and cultures were carried out as previously
described [10]. Cell confluence and morphology were
assessed throughout the experiments by phase-contrast
microscopy, as described elsewhere [20]. All experiments
were carried out by using primary synovial cells cultured
between passages 3 and 6.
Reagents
Human adrenomedullin (1-52) and (22-52)adrenomedul-
lin were purchased from Bachem. PBS, trypsin-EDTA,
and HAM F-12 were obtained from Invitrogen Life Tech-
nologies. Fetal calf serum (FCS) was from Dutscher; the
same batch was used in all experiments. Fibronectin,
vitronectin, Coll.I, bovine serum albumin (BSA), RAMP-
2 siRNA, RGD and scrambled peptides, and the PKA
inhibitor H-89 were purchased from Sigma-Aldrich.
CD49b (a2) Fluorescein IsoThioCyanate (FITC)-conju-
gated antibody, CD29 (b1) phycoerythrin (PE)-conju-
gated antibody, PE Mouse IgG2a, and FITC Mouse IgG1
( i s o t y p ec o n t r o l s )w e r eb o u g h tf r o mB DP h a r m i n g e n .
Paraformaldehyde (PFA) was purchased from Panreac.
Adhesion assay
The wells of 96-well flat-bottomed plates were coated
overnight at 4°C with 100 μlo ft h r e eE C Mp r o t e i n s ,a t
the following optimal doses defined in preliminary
experiments: vitronectin, 0.1 μg/cm
2; fibronectin, 0.01
μg/cm
2;a n dC o l l . I ,0 . 1μg/cm
2. BSA 0.1% and polylysin
0.1 μg/cm
2 were used as nonspecific controls. Wells
were blocked with 0.1% BSA for 1 hour at room tem-
perature (RT). Then FLSs previously cultured in HAM-
F12 10% FCS were harvested with trypsin-EDTA,
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with Ca
2+ and Mg
2+ to allow integrin activation.
To investigate the effect of adrenomedullin, we incu-
bated FLS at RT for 1 hour with adrenomedullin at indi-
cated concentrations. After washing, 10
5 cells were
seeded in each well and incubated for different periods at
37°C. Each condition was done in quadruplicate. After
incubation, unbound cells were removed along with the
culture medium. Remaining adherent cells were colored
for 15 minutes with 0.5% violet crystal and fixed with
20% methanol. Plates were washed twice with 300 μlo f
PBS 1X, and adherent cells were lysed with 1% SDS.
Adhesion was quantified with spectrophotometric optic-
density measurement at 550 nm (Dynatech MR5000).
To study the effects of the adrenomedullin receptor
antagonist (22-52)AM, of the PKA inhibitor H-89, and of
RGD peptide (integrin competitor), FLSs were preincu-
bated with (22-52)AM or H-89 at 10
-8,1 0
-7,o r1 0
-6 M,o r
with RGD (50, 100, 150 μg/ml; or scrambled peptide (150
μg/ml) as control) for 30 minutes and then treated with
adrenomedullin or left untreated for 1 additional hour.
The adhesion assay was performed as described earlier.
Small interference RNA
To silence RAMP-2 expression in RA-FLS, an siRNA,
ID number SASI_Hs01_00149404 [EBI:NM_005854],
was used. Cells were transfected by using the INTER-
FERIN transfection reagent (Ozyme) according to the
manufacturer’s instructions. siRNA was diluted in trans-
fection reagent and culture medium, and cells were
incubated with siRNA (5, 10, and 20 nM)f o r2 4h
before being processed for adhesion assay.
Fluorescence microscopy
FLSs were incubated for 1 hour with 10
-7 M adrenome-
dullin and washed. Then, 10
5 cells were plated on eight-
well LabTek uncoated coverslips (Nunc A/S) for 2 hours
at 37°C. After incubation, nonadherent cells were
removed along with the culture medium. The cells were
fixed with 4% PFA in PBS. Nonspecific sites were
blocked with 3% BSA in PBS for 1 hour at RT. For
immunostaining, cells were incubated for 1 hour with
both monoclonal AK-7 a2- FITC and HUTS-21 b1-PE
antibodies (Mc Ab) diluted 1/40 in 3% BSA. As a nega-
tive control, cells were incubated with g2-FITC and g1-
PE isotype control. The nuclei were then stained with
DAPI for 5 minutes. Cells were mounted in fluorescent
mounting medium (Dako) and viewed by using a fluor-
escence microscope (Nikon) interfaced with the software
package Microvision Instrument.
Where indicated, FLSs were preincubated with 10
-6 M
(22-52)AM for 30 minutes before being treated with
adrenomedullin or left untreated for 1 hour and then
processed for fluorescence microscopy, as described.
Talin immunoprecipitation and Western blotting
At confluence, FLSs were harvested with trypsin-EDTA,
pelleted, and resuspended in HAM-F12 without FCS.
FLSs were incubated with adrenomedullin for 1 hour,
and 10
5 cells were seeded in triplicate for 2 hours. After
incubation, cell proteins were extracted in lysis buffer.
After centrifugation, the protein content of the superna-
tants was determined by using the Pierce protein assay.
For immunoprecipitation (IP), 1 μg of specific anti-talin
antibody (Santa-Cruz) was incubated overnight at 4°C in
a rotating device with Dynabeads Protein G (Dynal Bio-
tech, Invitrogen) and 100-μg aliquots of protein lysates.
The magnetic beads were placed on a magnet, washed 3
times, suspended in lysis buffer and 4× running buffer
(40% glycerol, 8% SDS, 0.250 M Tris (pH 6.8), and 0.8
mg bromophenol blue), and denatured for 5 minutes at
95°C. The magnetic beads were placed on a magnet, and
the denatured proteins were retained in 100 μl lysis buf-
fer, whereas the beads were discarded. Aliquots (30 μl)
were then subjected to electrophoresis resolved on
4-20% SDS-PAGE gel (Bio-Rad) and transferred onto
Hybond polyvinylidene difluoride membrane
(Amersham Biosciences). The membranes were incu-
bated for 1 hour with 1× blocking buffer and then
reacted overnight with anti-talin antibody diluted 1:500
in blocking solution. The membranes were washed and
incubated with the appropriate peroxidase-coupled sec-
ondary antibody. The signal was visualized by using a
chemiluminescence detection system (Bio-Rad).
Statistical analysis
The data are reported as mean ± SEM for adhesion
experiments (at least three separate experiments with
different donors). Groups were compared by using
ANOVA and post hoc tests (Fisher test). All values are
normalized for the control value. P values less than 0.05
were considered significant.
Results
Adrenomedullin increases rheumatoid FLS adhesion to
extracellular matrix proteins
RA-FLSs were treated with 10
-7 M adrenomedullin for 1
hour and studied in a 2-hour adhesion assay, as
described earlier. The 10
-7 M adrenomedullin signifi-
cantly enhanced RA-FLS adhesion to all three ECM pro-
teins (Figure 1a), with a 2.39-, 2.25-, and 1.65-fold
increase for vitronectin, fibronectin, and Coll.I, respec-
tively (all with P < 0.0001). No effect was seen with the
negative controls (BSA and polylysin). These results sug-
gest that adrenomedullin may specifically affect adhesion
to FLS integrins, which are receptors of ECM proteins.
We evaluated RA-FLS adhesion after exposure to var-
ious adrenomedullin concentrations. The adhesion-
enhancing effect increased in a dose-dependent manner:
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Page 3 of 11Figure 1 Adrenomedullin significantly and dose-dependently increases the adhesion of RA-FLSs to vitronectin, fibronectin, and type I
collagen. RA-FLSs are resuspended in HAM-F12 without fetal calf serum and incubated for 1 hour with adrenomedullin (AM) at the indicated
concentrations. Then 10
5 cells with or without adrenomedullin are seeded on 96-well plates previously coated overnight with the extracellular
matrix proteins, bovine serum albumin (BSA), or polylysin. After 2-hour adhesion, nonadherent cells are removed, and the remaining RA-FLSs are
stained with violet crystal for 15 minutes. The plates are washed, and the cells are lysed. Adherent cells are quantified by measuring absorbance
at 550 nm with a spectrophotometer. (a) Effect of AM on RA-FLS adhesion to different surfaces. (b) The effect of AM is dose dependent. (c)
Phase-contrast microscopy photographs demonstrating adhesion of RA-FLSs to BSA (negative control) and vitronectin with or without 10
-7 M
AM. (d) Time course of RA-FLSs adhesion to vitronectin under basal conditions (left panel) and with AM (right panel). Bars indicate mean ± SEM.
*P < 0.05; **P < 0.01; ***P < 0.0001 versus control;
##P < 0.01 and
###P < 0.0001 versus 10
-10 M AM; and,
§§P < 0.01 and
§§§P < 0.0001 versus 10
-9
M AM. Results are given as the ratio of optical density (OD) in each condition over control OD without AM and reported as mean ± SEM of
three experiments (three different donors) performed in quadruplicate.
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Page 4 of 111.41-fold with 10
-8 M (P = 0.04); twofold with 10
-7 M
(P < 0.0001) of adrenomedullin; 1.6-fold at 10
-8 M (P =
0.0001); and 1.7-fold at 10
-7 M (P < 0.0001) on vitronec-
tin and fibronectin, respectively (Figure 1b, middle
panel). RA-FLS adhesion to Coll.I was dose-dependently
increased by 1.4-, 1.7-, 1.8-, and 1.5-fold; P =0 . 0 2 ,P <
0.0001, P < 0.0001, and P = 0.005 with 10
-9 M to 10
-6
M A M ,r e s p e c t i v e l y( F i g u r e1 b ,r i g h tp a n e l ) .R A - F L S s
exposed to adrenomedullin exhibited a spread-out shape
on vitronectin after 2 hours, whereas the cells remained
round on BSA (Figure 1c); no cell-to-cell adhesion was
observed at higher-power field (not shown).
A time-course experiment was designed by using dif-
ferent incubation periods (15, 30, 60, and 120 minutes)
with vitronectin only. Spontaneous RA-FLSs adhesion
increased gradually with time from 0.43 OD at 15 min-
utes to 1.52 OD at 2 hours (Figure 1d, i). By contrast,
the effect of adrenomedullin on RA-FLSs adhesion was
already maximal after 15 minutes (2.2-fold increase; P <
0.0001). Nevertheless, this effect remained significant
(1.4-fold increase, P = 0.02) after 2 hours (Figure 1d, ii).
Furthermore, after 2 hours, adrenomedullin-stimulated
RA-FLSs had a typical spread-out fibroblast-like shape,
contrasting with the round, loosely bound shape seen
after 15 minutes. In subsequent experiments, we used
the 2-hour period associated with firmer attachment.
The adrenomedullin effect is specific of rheumatoid FLSs
adhesion
Given previous evidence that RA-FLSs expressed more
adrenomedullin and adrenomedullin receptors (CLR/
RAMP-2 and CLR/RAMP-3) than did OA-FLS [10], we
compared the effect of adrenomedullin on RA-FLSs and
OA-FLSs. After 2 hours, basal adhesion to all three
ECM proteins was not significantly different between
RA-FLSs and OA-FLSs (Figure 2a). Adrenomedullin sig-
nificantly increased RA-FLSs adhesion (P < 0.0001 for
a l lc o m p a r i s o n s )b u th a dn oe f f e c to nO A - F L S sa d h e -
sion (Figure 2b). This constitutes the first evidence that
the adhesion-enhancing effect of adrenomedullin is spe-
cific of RA-FLSs, at least in vitro.
The adhesion-enhancing effect of adrenomedullin is
mediated by the adrenomedullin receptor CLR/RAMP
To investigate the role of adrenomedullin and its recep-
tors in RA-FLSs adhesion, we preincubated the cells
with (22-52)adrenomedullin ,as p e c i f i ca n t a g o n i s to f
adrenomedullin receptors [10]. Without exogenous
adrenomedullin, (22-52)adrenomedullin had no effect
on RA-FLS adhesion as compared with control, even at
(22-52)adrenomedullin highest concentration (10
-6 M)
(decrease by 20%; P = 0.08) (Figure 3a). Adrenomedullin
alone (10
-7 M) significantly increased RA-FLSs adhesion
(1.4-fold; P = 0.009). This increase was significantly and
dose-dependently inhibited by (22-52)adrenomedullin
(decrease by 26%, 46%, 35%, 38%, and 71%; P = 0.02;
P = 0.0002; P = 0.0004; P = 0.0002; and P <0 . 0 0 0 1
with 10
-10,1 0
-9,1 0
-8,1 0
-7,a n d1 0
-6 M, respectively)
(Figure 3a).
To confirm further the role for the adrenomedullin
receptor and downstream signaling molecules, we used
the pharmacologic PKA inhibitor H-89. Basal RA-FLS
adhesion was significantly and dose-dependently
decreased by H-89 (0.51-fold to 0.66-fold; P =0 . 0 0 5 )
(Figure 3b). Moreover, adrenomedullin-enhanced RA-
FLSs adhesion (1.4-fold; P = 0.05) was significantly
decreased by H-89 (0.36-fold to 0.6-fold; P = 0.002).
Finally, RAMP-2 siRNA enabled us to inhibit the AM
co-receptor because it inhib i t e dA M - i n d u c e da d h e s i o n
by 48%, 62%, and 72% (P < 0.0001) with 5, 10, and
20 nM RAMP-2 siRNA, respectively (Figure 3c).
Adrenomedullin-enhanced rheumatoid FLSs adhesion is
linked to integrin activation
The specific and early effect of adrenomedullin on RA-
FLS adhesion to ECM proteins suggested activation of
latent adhesion molecules. Therefore, we evaluated the
role of integrins in FLSs adhesion. RGD peptide (an
integrin competitor) inhibited basal and AM-stimulated
RA-FLSs adhesion in a dose-dependent manner, whereas
the scrambled peptide had no effect (Figure 4a).
We then evaluated the effect of adrenomedullin on
integrin activation. A number of monoclonal antibodies
recognize “activation” epitopes (extracellular portions of
the integrin molecule that are present only when its
ligand is bound). We then used HUTS-21 and AK-7,
which specifically recognize the activated b1 [21,22] and
a2 integrin subunits, respectively. Adrenomedullin sig-
nificantly increased the expression of both activated a2
(1.7-fold; P =0 . 0 2 )a n db1 subunits (1.5-fold; P =0 . 0 5 )
(Figure 4b, c). Co-localization of the activated a2 and b1
integrins was visible on the merged view (Figure 4b,
right panel).
Moreover, we tested the hypothesis that adrenomedul-
lin enhanced the interaction of talin with the b1 subunit,
thereby causing integrin activation. The b1 subunit co-
immunoprecipitated with talin, confirming that the two
proteins are associated in a complex. Immunoblotting
showed that adrenomedullin increased the talin-b1 inter-
action (Figure 4d).
The receptor antagonist (22-52)adrenomedullin inhibits
adrenomedullin-related integrin activation
Because adrenomedullin exerted its effects on RA-FLS
through the CLR-RAMP receptor, we pretreated RA-
FLSs with 10
-6 M (22-52)adrenomedullin, for 30 minutes,
before adding 10
-7 M adrenomedullin (Figure 5). After
2-hour adhesion, 10
-7 M adrenomedullin significantly
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fold and 1.4-fold, respectively, compared with controls.
The (22-52)adrenomedullin significantly decreased AM-
stimulated a2 (Figure 5a) and b1 (Figure 5b) subunits
expression to control level. However, (22-52)adrenome-
dullin alone had no effect on activated integrin expres-
sion, compared with control RA-FLSs.
Discussion
This study provides the first evidence that adrenomedul-
lin increases RA-FLS-integrin-dependent adhesion to
several cartilage and bone ECM proteins by activating
integrins, or at least their a2 and b1 subunits (Figure 6).
Of note, this effect was observed only with RA-FLSs and
not with OA-FLSs. Integrin activation was mediated by
the adrenomedullin receptors CLR/RAMP, because it
was inhibited by the receptor antagonist (22-52)AM, by
inhibition of PKA, a downstream signaling molecule,
and by inhibition of RAMP-2 by siRNA. Moreover, we
obtained indirect evidence of integrin activation through
a talin-dependent pathway.
Adrenomedullin increased RA-FLSs adhesion to the
ECM proteins vitronectin, fibronectin, and Coll.I, which
are abundant in the rheumatoid pannus. Increased levels
of fibronectin have been found in rheumatoid synovial
tissues [23-25]. Vitronectin was increased in the synovial
lining layer from both OA and RA tissues, compared
with normal tissues [26]. The expression of several
integrin-receptor subunits is also increased in situ.
Rheumatoid synovial tissues express high levels of the
a1 to a6 subunits, and of the b1, b3,a n db4 subunits,
but low levels of the av subunit [7,27,28]. The overex-
pressed integrins include a5b1 and avb3 (the vitronectin
receptor) and a2b1 (the Coll.I receptor). Coll.I accounts
for 90% of the organic matrix of mineralized bone [29],
and RA is characterized by bone invasion and erosion
[30], a process preceded by attachment of RA-FLSs to
the articular cartilage [31]. For these reasons, we
selected fibronectin, vitronectin, and Coll.I for our study
of RA-FLS adhesion.
Few studies have compared OA-FLSs and RA-FLSs
adhesion to cartilage and bone ECM proteins [32]. Schedel
et al. [32] showed that OA-FLSs and RA-FLSs adhered
more strongly to types I, II, and VI collagens than to BSA,
with no difference between OA and RA cells. These results
are consistent with our finding that basal adhesion to Coll.
Figure 2 Effect of adrenomedullin on adhesion of rheumatoid and osteoarthritic fibroblast-like synoviocytes (RA-FLSs and OA-FLSs,
respectively). RA-FLSs or OA-FLSs are incubated for 1 hour with or without 10
-7 M adrenomedullin (AM) and seeded for 2 hours on 96-well plates
coated with the ECM proteins. The number of adherent cells is assessed by using colorimetry. Bars indicate mean ± SEM. *P < 0.05; ***P < 0.0001.
Results are given as the ratio of optical density (OD) in each condition over control OD without adrenomedullin and reported as mean ± SEM of
three experiments (different donors) performed in quadruplicate. (a) Comparison of basal adhesion of RA-FLSs and OA-FLSs with vitronectin,
fibronectin, and type I collagen. (b) Effect of 10
-7 M AM on RA-FLSs and OA-FLSs adhesion to vitronectin, fibronectin, and type I collagen.
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Page 6 of 11Figure 3 Adrenomedullin exerts its action on RA fibroblast adhesion through CLR/RAMP receptors.R A - F L S sw e r ei n c u b a t e df o r3 0
minutes with various concentrations of (22-52)AM, or H-89, or for 24 hours with siRNA-RAMP-2 and then with or without soluble
adrenomedullin (AM) for 1 hour. (22-52)AM, H-89, and siRNA RAMP-2 inhibited the adhesion-enhancing effect of AM. Bars indicate mean ± SEM.
***P < 0.0001;
###P < 0.0001 versus 10
-7 M AM, and
§P < 0.05. Results are given as the ratio of OD in each condition over control OD without AM
and reported as mean ± SEM of two experiments (different donors) performed in quadruplicate. (a) Dose-dependent effect of (22-52)AM on
basal and AM-stimulated RA-FLSs adhesion. (b) Dose-dependent effect of H-89 on basal and AM-stimulated RA-FLSs adhesion in each condition
over OD of control. (c) Dose-dependent effect of siRNA RAMP-2 on AM-stimulated RA-FLSs adhesion in each condition over OD of control.
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Page 7 of 11Figure 4 Adrenomedullin significantly increases cell-surface expression of activated a2 and b1 integrins by rheumatoid fibroblast-like
synoviocytes (RA-FLSs). RA-FLSs were incubated with 10
-7 M adrenomedullin (AM), or without AM as a control, for 1 hour. Bars indicate mean
± SEM. *P < 0.05; **P < 0.01; ***P < 0.0001. Inhibition adhesion study was done with RGD peptides and scrambled peptide for 30 minutes
before AM stimulation. A fluorescence microscope was used for visualization of three sections and image capture. The mean ratio of fluorescent
cells from these three sections was calculated as the ratio of the number of fluorescent cells over total cells counted by DAPI staining. Results
are given as the ratio of fluorescent cells over control cells without AM and reported as the mean ± SEM of three experiments (three different
donors) performed in triplicate. For IP, cell lysates from nonstimulated and AM-stimulated RA-FLSs were immunoprecipitated with anti-talin and
then immunoreacted with anti-b1 with Western blot analysis (The figure is representative of two experiments done with two different RA-FLSs).
(a) Dose-dependent inhibition of FLSs adhesion by using RGD peptides. Left panel, basal adhesion; right panel, AM stimulation. (b) Observation
with fluorescence microscopy of the distribution of activated a2 and b1 integrin expression in RA-FLSs with or without 10
-7 M AM. Insert shows
rim pattern or cytoplasmic membrane expression of activated integrin. (c) Effect of 10
-7 M adrenomedullin on the number of RA-FLSs expressing
activated a2 and b1 integrins. (d) IP: Effect of 10
-7 M AM on the talin-b1 integrin interaction.
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FLSs. Rinaldi et al. [7] showed that isolated RA-FLSs were
significantly more adherent than normal FLSs to fibronec-
tin, but also to other ECM proteins such as laminin and
tenascin, a protein involved in RA synovium remodeling.
However, no previous studies compared RA-FLSs and
OA-FLSs regarding basal adhesion to vitronectin and
fibronectin; we found no difference between RA and OA
cells. We cannot assume a complete specificity of the adre-
nomedullin effect in RA because we have not tested other
FLSs derived from psoriatic arthritis, as an example.
We found that adrenomedullin specifically increased
RA-FLS adhesion to ECM proteins but had no effect on
OA-FLS adhesion. This difference may be ascribable to
Figure 5 (22-52)AM inhibits adrenomedullin-induced activation of a2 and b1 integrins on rheumatoid fibroblast-like synoviocytes (RA-
FLSs). RA-FLSs were incubated for 30 minutes with various concentrations of (22-52)adrenomedullin (AM) or H-89 and then with or without
soluble AM for 1 hour. Bars indicate mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.0001. A fluorescence microscope was used for visualization of
three sections and image capture. The mean ratio of fluorescent cells from these three sections was calculated as the ratio of the number of
fluorescent cells over total cells counted with DAPI staining. Results are given as the ratio of fluorescent cells over control cells without AM and
reported as the mean ± SEM of three experiments (three different donors) performed in triplicate. (a) Mean fluorescence ratio of activated a2-
subunit expression. (b) Mean fluorescence ratio of activated b1-subunit expression.
Figure 6 Model of adrenomedullin-induced regulation of rheumatoid fibroblast-like synoviocyte (RA-FLS) adhesion by the CLR-RAMP/
PKA pathway. Adrenomedullin (AM) activates RA-FLS adhesion to the extracellular matrix proteins vitronectin, fibronectin, and type I collagen.
The AM-receptor antagonist (22-52)AM and silencing of RAMP-2 inhibited AM-induced RA-FLS adhesion of CLR/RAMP results in activation of PKA,
as assessed by its inhibition by H-89. AM triggers a talin-b1 chain interaction, disrupting the salt bridge between the a and b subunits and
thereby activating the integrins, explaining the increase in RA-FLS adhesion.
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(CLR/RAMP2) mRNA and proteins by RA-FLSs than by
OA-FLSs [10]. Moreover, our inhibition experiments
using an adrenomedullin-receptor antagonist, an inhibi-
tor of PKA, and one RAMP-2 siRNA confirmed the role
for adrenomedullin receptors. It should be mentioned
that no in vitro receptor binding kinetics compared (22-
52)adrenomedullin with adrenomedullin.
Our findings suggest that the effect of adrenomedullin
may be specific for adhesion molecules, such as integrins.
The effect of adrenomedullin on RA-FLSs adhesion was
already at its peak after 15 minutes, when adhesion was
loose, whereas after 2 hours, the RA-FLSs exhibited the
typical spreadout fibroblast-like appearance. In our
attempt to demonstrate early adhesion-molecule expres-
sion, we selected integrins, because these are presynthe-
sized in an inactive form and expressed at the membrane
cell surface, and they are natural receptors for ECM pro-
teins. With the specific antibodies AK7 and HUTS-21,
we found that adrenomedullin induced integrin activa-
tion through a mechanism involving the adrenomedullin
receptors. Integrin-mediated cell adhesion has been
shown to depend on cAMP/PKA [33].
We studied only the a2 and b1 integrin subunits, which
are involved in cell adhesion, not only to Coll.I and fibro-
nectin, but also to other ECM molecules of interest, such
as type II collagen [7]. The signaling pathways leading
from CLR-AC-PKA activation to integrin activation are
unknown. However, we hypothesized that talin, a major
integrin activator, was activated by adrenomedullin. As
siRNA would inhibit not only adrenomedullin-stimulated
adhesion, but also basal adhesion, we chose talin IP fol-
lowed by integrin b1 immunoblotting to investigate the
interaction of the two proteins with adrenomedullin. We
found that adrenomedullin stimulated integrin activation
by increasing this talin-b1 interaction. Moreover, by
using the adrenomedullin-receptor antagonist (22-52)
AM, we were able to confirm the role for adrenomedullin
in a2 and b1 integrin activation.
Previous studies have established that adrenomedullin
activates adhesion molecules in other cell types. With
HUVECs, adrenomedullin induces cell-surface expres-
sion of E-selectin, vascular cell adhesion molecule
(VCAM-1), and ICAM-1 [17], through adenylate cyclase
activation. These studies investigated only the effect of
adrenomedullin on adhesion-molecule expression,
whereas we used a reproducible functional adhesion
assay to study FLSs adhesion in addition to integrin
activation.
Adrenomedullin also increased capillary cell activation
and neoangiogenesis in various animal models of tissue
repair or tumor growth [34,35]. Angiogenesis occurs in
the rheumatoid pannus and is an early event in collagen-
induced arthritis [36]. Adrenomedullin [37] and (22-52)
adrenomedullin [38] can stimulate or inhibit the spread
of metastases in vivo, respectively. Cell adhesion is the
first event in a multistep process and is followed by
migration and invasion in angiogenesis, tumor growth,
and invasiveness. We have obtained preliminary evidence
supporting a role for adrenomedullin in increasing RA-
FLSs migration in a two-dimensional system (Asensio
and Ah Kioon, unpublished data). Overall, adrenomedul-
lin may contribute to cell adhesion, migration, prolifera-
tion, and reduced apoptosis. These events are involved
not only in pannus progression but also in tumor devel-
opment, indicating a new role for adrenomedullin.
Conclusions
In this work, we showed that soluble adrenomedullin
increases RA-FLSs adhesion to various ECM proteins
expressed in synovial tissue, cartilage, or bone. This
effect is mediated by the adrenomedullin receptor CLR,
and it does not occur with OA-FLSs, which express
fewer adrenomedullin receptors [10]. This adrenomedul-
lin-dependent RA-FLSs adhesion is ascribable to activa-
tion of the talin-b1 interaction followed by integrin
activation (Figure 6). Thus, adrenomedullin may partici-
pate in the regulation of RA-FLSs and therefore to some
extent in the pathogenesis of RA.
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